Your browser doesn't support javascript.
loading
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
Lu, Zhihao; Wang, Junye; Shu, Yongqian; Liu, Lianke; Kong, Li; Yang, Lei; Wang, Buhai; Sun, Guogui; Ji, Yinghua; Cao, Guochun; Liu, Hu; Cui, Tongjian; Li, Na; Qiu, Wensheng; Li, Gaofeng; Hou, Xinfang; Luo, Hui; Xue, Liying; Zhang, Yanqiao; Yue, Wenbin; Liu, Zheng; Wang, Xiuwen; Gao, Shegan; Pan, Yueyin; Galais, Marie-Pierre; Zaanan, Aziz; Ma, Zhuo; Li, Haoyu; Wang, Yan; Shen, Lin.
Afiliación
  • Lu Z; Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
  • Wang J; Department of Oncology, The Affiliated Hospital of Jining Medical College, Jining, China.
  • Shu Y; Department of Medical Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Liu L; Department of Medical Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Kong L; Special Needs Ward, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
  • Yang L; Department of Medical Oncology, Nantong Tumour Hospital, Nantong, China.
  • Wang B; Department of Medical Oncology, Northern Jiangsu People's Hospital, Affiliated Hospital to Yangzhou University, Yangzhou, China.
  • Sun G; Department of Radiotherapy and Chemotherapy, Tangshan People's Hospital, Tangshan, China.
  • Ji Y; Department of Medical Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
  • Cao G; Department of Oncology, Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing, China.
  • Liu H; Department of Medical Oncology, Anhui Provincial Cancer Hospital, University of Science and Technology of China, Hefei, China.
  • Cui T; Department of Oncology, Fujian Provincial Hospital, Fuzhou, China.
  • Li N; Department of Medical Oncology, Suining Central Hospital, Suining, China.
  • Qiu W; Department of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Li G; Department of Thoracic Surgery Ward 2, Yunnan Cancer Hospital, Kunming, China.
  • Hou X; Department of Medical Oncology, Henan Tumour Hospital, Zhengzhou, China.
  • Luo H; Department of Thoracic Tumour Radiotherapy Ward 2, Jiangxi Cancer Hospital, Nanchang, China.
  • Xue L; Department of Medical Oncology, Inner Mongolia People's Hospital, Hohhot, China.
  • Zhang Y; Department of Digestive Oncology Ward 2, Harbin Medical University Cancer Hospital, Harbin, China.
  • Yue W; Department of Medical Oncology, Puyang Oilfield General Hospital, Puyang, China.
  • Liu Z; Department of Medical Oncology Three, Handan Central Hospital, Handan, China.
  • Wang X; Department of Oncology, Qilu Hospital of Shandong University, Jinan, China.
  • Gao S; Oncology Department, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
  • Pan Y; Department of Tumour Chemotherapy, Anhui Provincial Hospital, Hefei, China.
  • Galais MP; Department of Medical Oncology, Centre François Baclesse, Caen, France.
  • Zaanan A; Department of Gastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, Paris, France.
  • Ma Z; Medical Science and Strategy Oncology, Innovent Biologics, China.
  • Li H; Department of Statistics, Innovent Biologics, China.
  • Wang Y; Medical Science and Strategy Oncology, Innovent Biologics, China.
  • Shen L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China linshenpku@163.com.
BMJ ; 377: e068714, 2022 04 19.
Article en En | MEDLINE | ID: mdl-35440464
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Protocolos de Quimioterapia Combinada Antineoplásica / Anticuerpos Monoclonales Humanizados / Carcinoma de Células Escamosas de Esófago Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Humans Idioma: En Revista: BMJ Asunto de la revista: MEDICINA Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Protocolos de Quimioterapia Combinada Antineoplásica / Anticuerpos Monoclonales Humanizados / Carcinoma de Células Escamosas de Esófago Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Humans Idioma: En Revista: BMJ Asunto de la revista: MEDICINA Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido